Horizon Therapeutics Touts Five New Development Programs on R&D Day

Horizon Therapeutics updated its new development programs at its Virtual R&D Day. Of note, the company was adding five new development programs for daxdilimab (HZN-7734) and dazodalibep (HZN-4920). This brings the company’s pipeline to 27 development programs.